Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...